Form 4: Ligand Pharmaceuticals CLO Executes Stock Sale

Ligand Pharmaceuticals Chief Legal Officer Andrew Reardon exercised options and sold 5,000 shares of common stock.

Summary

• Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised options to acquire 5,000 shares at $52.27 per share.
• Following the acquisition, the reporting person sold the 5,000 shares in multiple transactions at weighted-average prices ranging from $223.95 to $230.41.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-arranged 10b5-1 plan, which is a routine mechanism for executive financial planning.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The executive retains a significant beneficial ownership of 41,382 shares following the transaction.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• None identified in this specific Form 4 filing.

Future Outlook

No forward-looking guidance provided in this document.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executive liquidity and does not necessarily reflect a change in management's outlook on the company's long-term prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential allegations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-established, automated trading plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Executive Compensation, Stock Options